Cyxone AB (Sweden) Today
| CYXO Stock | SEK 0.14 0.01 7.69% |
Performance13 of 100
| Odds Of DistressOver 51
|
Cyxone AB is selling for under 0.14 as of the 18th of June 2024; that is 7.69 percent increase since the beginning of the trading day. The stock's last reported lowest price was 0.13. Cyxone AB has 51 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. Equity ratings for Cyxone AB are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of May 2024 and ending today, the 18th of June 2024. Click here to learn more.
Cyxone AB , a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis and treatments for virally induced acute respiratory disorders. The company was founded in 2015 and is headquartered in Malm, Sweden. The company has 98.44 M outstanding shares. More on Cyxone AB
Moving together with Cyxone Stock
Moving against Cyxone Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cyxone Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cyxone AB's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cyxone AB or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Ola Skanung |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Cyxone AB (CYXO) is traded on Stockholm Exchange in Sweden and employs 8 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.96 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cyxone AB's market, we take the total number of its shares issued and multiply it by Cyxone AB's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cyxone AB operates under Healthcare sector and is part of Biotechnology industry. The entity has 98.44 M outstanding shares.
Cyxone AB has accumulated about 56.34 M in cash with (43.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cyxone AB Probability Of Bankruptcy
Ownership AllocationCyxone AB holds a total of 98.44 Million outstanding shares. Cyxone AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cyxone Ownership Details
Cyxone AB Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cyxone AB market risk premium is the additional return an investor will receive from holding Cyxone AB long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cyxone AB. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cyxone AB's alpha and beta are two of the key measurements used to evaluate Cyxone AB's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 4.08 | |||
| Semi Deviation | 4.38 | |||
| Standard Deviation | 5.91 | |||
| Variance | 34.98 |
Cyxone Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cyxone AB without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.